Capricor's Duchenne drug gets three-month FDA extension after new data submission
- Posted on August 24, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Capricor's Duchenne drug gets three-month FDA extension after new data submission
By Kamal Choudhury Aug 24 (Reuters) - Capricor Therapeutics said on Monday the U.S. Food and Drug Administration had extended the review period for its experimental cell therapy for Duchenne muscular dystrophy by three months. The delay follows Capricor's submission of new 24-month data from its late-stage study, along with extra analyses, to support a refined proposed indication focused on
